19516 Federal Register / Vol. 87, No. 64 / Monday, April 4, 2022 / Notices 

Regulatory Secretariat Division, by 

calling 202–501–4755 or emailing 

GSARegSec@gsa.gov. Please cite OMB 

Control No. 9000–0082, Federal 

Acquisition Regulation Part 7 

Requirements. 

Janet Fry, 

Director, Federal Acquisition Policy Division, 

Office of Governmentwide Acquisition Policy, 

Office of Acquisition Policy, Office of 

Governmentwide Policy. 

[FR Doc. 2022–06992 Filed 4–1–22; 8:45 am] 

BILLING CODE 6820–EP–P 

GOVERNMENT ACCOUNTABILITY 

OFFICE 

Request for Nominations for the Board 

of Governors of the Patient-Centered 

Outcomes Research Institute (PCORI) 

AGENCY: Government Accountability 

Office (GAO). 

ACTION: Request for letters of 

nomination and resumes. 

SUMMARY: The Patient Protection and 

Affordable Care Act gave the 

Comptroller General of the United 

States responsibility for appointing up 

to 21 members to the Board of 

Governors of the Patient-Centered 

Outcomes Research Institute. In 

addition, the Directors of the Agency for 

Healthcare Research and Quality and 

the National Institutes of Health, or their 

designees, are members of the Board. As 

the result of terms ending in September 

2022, GAO is accepting nominations in 

the following categories: A surgeon, a 

state-licensed integrative health care 

practitioner, a representative of patients 

and health care consumers, a 

representative of device manufacturers 

or developers, a representative of 

pharmaceutical manufacturers or 

developers, and a representative of 

private payers who represents health 

insurance issuers. Nominations should 

be sent to the email address listed 

below. Acknowledgement of 

submissions will be provided within a 

week of submission. 

DATES: Letters of nomination and 

resumes should be submitted no later 

than May 10, 2022, to ensure adequate 

opportunity for review and 

consideration of nominees prior to 

appointment. 

ADDRESSES: Submit letters of 

nomination and resumes to PCORI@

gao.gov. Include PCORI Nomination in 

the subject line of the email. 

FOR FURTHER INFORMATION CONTACT: Ray 

Sendejas at (202) 512–7113 or 

SendejasR@gao.gov if you do not 

receive an acknowledgement or need 

additional information. For general 

information, contact GAO’s Office of 

Public Affairs, (202) 512–4800. 

Authority: Sec. 6301 and Sec. 10602, 

Pub. L. 111–148, 124 Stat. 119, 727, 

1005 (2010); Div. N, Sec. 104, Pub. L. 

116–94, 133 Stat. 2534 (2019). 

Gene L. Dodaro, 

Comptroller General of the United States. 

[FR Doc. 2022–06452 Filed 4–1–22; 8:45 am] 

BILLING CODE 1610–02–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2022–0044] 

CDC Recommendations for Hepatitis B 

Screening and Testing—United States, 

2022; Request for Comment 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

opening of a docket to obtain comment 

on proposed updated recommendations 

for hepatitis B virus (HBV) infection 

screening and testing (Proposed 

Updated Recommendations), including 

hepatitis B screening at least once in a 

lifetime for persons 18 years of age and 

older, using a three-test panel. The 

Proposed Updated Recommendations 

also expand existing risk-based testing 

recommendations to include the 

following populations, activities, 

exposures, or conditions associated with 

increased risk for HBV infection: 

Persons currently or formerly 

incarcerated in a jail, prison, or other 

detention setting; persons with a history 

of sexually transmitted infections or 

multiple sex partners; and persons with 

a history of hepatitis C virus infection. 

The Proposed Updated 

Recommendations are intended to 

inform the practices of and care by U.S. 

healthcare providers and are based on 

scientific evidence of the effectiveness 

and economic value of screening to 

diagnose current HBV infection among 

adults in the United States. 

DATES: Written comments must be 

received on or before June 3, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0044, by either of the following 

methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Viral Hepatitis, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop U12–3, Atlanta, GA 30329, 

Attn: Docket No. CDC–2022–0044. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. Do not 

submit comments by email; CDC does 

not accept comments by email. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Erin 

Conners, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop U12–3, Atlanta, GA 30329; 

Telephone: 404–639–8000; Email: 

DVHpolicy@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data related to any of the Proposed 

Updated Recommendations or 

supporting evidence. In addition, CDC 

invites comments specifically on the 

following questions: 

• Based on the evidence presented in 

the full recommendations document 

(see the Supporting and Related 

Materials tab in the docket), does the 

evidence support the Proposed Updated 

Recommendations for HBV infection 

screening and testing? If not, please 

state the reason why and, if available, 

provide additional evidence for 

consideration. 

• Are CDC’s Proposed Updated 

Recommendations (see Supporting and 

Related Materials) clearly written? If 

not, what changes do you propose to 

make them clearer? 

• If implemented as currently drafted, 

do you believe the Proposed Updated 

Recommendations would result in a 

reduction in HBV infections and 

associated health and financial 

consequences (e.g., patient and 

healthcare costs to treat chronic 

hepatitis B) in the United States? If not, 

please provide an explanation and 

supporting data or evidence. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 


khammond on DSKJM1Z7X2PROD with NOTICES